Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

Background CheckMate 025 has shown superior efficacy for nivolumab over everolimus in patients with advanced renal cell carcinoma (aRCC) along with improved safety and tolerability. This analysis assesses the long‐term clinical benefits of nivolumab versus everolimus. Methods The randomized, open‐la...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer Jg. 126; H. 18; S. 4156 - 4167
Hauptverfasser:	Motzer, Robert J., Escudier, Bernard, George, Saby, Hammers, Hans J., Srinivas, Sandhya, Tykodi, Scott S., Sosman, Jeffrey A., Plimack, Elizabeth R., Procopio, Giuseppe, McDermott, David F., Castellano, Daniel, Choueiri, Toni K., Donskov, Frede, Gurney, Howard, Oudard, Stéphane, Richardet, Martin, Peltola, Katriina, Alva, Ajjai S., Carducci, Michael, Wagstaff, John, Chevreau, Christine, Fukasawa, Satoshi, Tomita, Yoshihiko, Gauler, Thomas C., Kollmannsberger, Christian K., Schutz, Fabio A., Larkin, James, Cella, David, McHenry, M. Brent, Saggi, Shruti Shally, Tannir, Nizar M.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Wiley Subscription Services, Inc 15.09.2020
Schlagworte:	advanced renal cell carcinoma (aRCC) Antiangiogenics Cancer CheckMate 025 Clear cell-type renal cell carcinoma everolimus Fatigue immune checkpoint inhibitor Immune checkpoint inhibitors Immunotherapy Inhibitor drugs Kidney cancer Kidneys Monoclonal antibodies nivolumab Oncology Patients previously treated Pruritus Quality of life Randomization Renal cell carcinoma Safety Safety management Stomatitis Survival Targeted cancer therapy Toxicity previously treated CheckMate 025 advanced renal cell carcinoma (aRCC) everolimus immune checkpoint inhibitor nivolumab
ISSN:	0008-543X, 1097-0142, 1097-0142
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!